Key statistics dashboard for Evaxion Biotech A/S (EVAX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases.
Stock Data
| Price | $3.03 |
| Market Cap | $19M |
| Beta | 0.20 |
| Exchange | NASDAQ |
| Country | DK |
Valuation Multiples
| P/E Ratio | -0.52 |
| Price / Book | 0.14 |
| P/S | 2.67 |
| P/FCF | 0.00 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 100.00% |
| EBIT Margin | -132.50% |
| EBITDA Margin | -132.50% |
| Operating Margin | -115.98% |
| Net Margin | -115.49% |
Financial Health
| Current Ratio | 5.06 |
| Quick Ratio | 5.06 |
| Cash Ratio | 4.47 |
| Debt / Equity | 0.75 |
| Debt / Assets | 36.66% |
| Interest Coverage | -11.89 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -4.54 |
Per-Share Data
| Revenue per share | 17.97 |
| Book Value per share | 22.86 |
| Cash per share | 33.57 |
| FCF per share | 0.00 |
| Tangible Book Value per share | 22.86 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 1.00 |
Related companies: ANVS · BCAB · BTAI · CELU · GBIO · MURA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of EVAX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks